"
HIV Prevalence among HCV Egyptian Infected Patients and Its Impact on the Result of HCV Treatment"
written by Rabab Fouad, Olfat Shaker, Hanan Abdel Hafez, Rabab Salama, Mayssa El Raziky, Samar Marzouk, Wafaa El Akel, Marwa Abdel Ghany, Gamal Esmat,
published by
Advances in Infectious Diseases,
Vol.3 No.2, 2013
has been cited by the following article(s):
|
[1]
|
Effect of HCV treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker of intestinal permeability in HCV/HIV co-infected patients
Egyptian Liver Journal,
2023
DOI:10.1186/s43066-023-00255-x
|
|
|
|
|
[2]
|
Current situation of viral hepatitis in Egypt
Microbiology and Immunology,
2021
DOI:10.1111/1348-0421.12916
|
|
|
|
|
[3]
|
DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV
Expert Review of Gastroenterology & Hepatology,
2019
DOI:10.1080/17474124.2019.1614441
|
|
|
|
|
[4]
|
Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV
Liver International,
2017
DOI:10.1111/liv.13319
|
|
|
|
|
[5]
|
Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV
Liver International,
2017
DOI:10.1111/liv.13319
|
|
|
|